FY2025 · ended Jan 3, 2026 · Revenue $925.26M, +8.3% YoY · Filed Mar 16, 2026
Usana Health Sciences, Inc. (USNA) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In fiscal 2025, which ended Jan 3, 2026, it reported revenue of $925.3 million and net income of $10.8 million. Free cash flow was $8.5 million.
Revenue (TTM)
$913.36M
Net income (TTM)
$-22.16M
Operating cash flow (TTM)
$27.73M
Free cash flow (TTM)
$15.93M
EPS (TTM)
$-1.20
Dividend per share
None
Shares outstanding
18.46M
-2.4% vs prior year
Net cash
$140.42M
FY 2025
Operating margin
-0.1%
FY 2026
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- USNA (NYSE)
- Fiscal year ends
- January 3
- Incorporated in
- UT
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Accelerated filer
- SEC CIK
- 896264
- Former names
- USANA INC (until Apr 27, 2000)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Jan 3, 2026 |
FY 2023 Dec 28, 2024 |
FY 2023 Dec 30, 2023 |
FY 2022 Dec 31, 2022 |
FY 2022 Jan 1, 2022 |
|---|---|---|---|---|---|
| Revenue | $925.3M | $854.5M | $921.0M | $998.6M | $1.2B |
| Operating income | $37.4M | $66.3M | $93.1M | $107.6M | $170.2M |
| Net income | $10.8M | $42.0M | $63.8M | $69.3M | $116.5M |
| Diluted EPS | $0.58 | $2.19 | $3.30 | $3.59 | $5.73 |
| Operating cash flow | $22.3M | $61.0M | $70.6M | $103.9M | $121.2M |
| Free cash flow | $8.5M | $50.9M | $56.1M | $93.5M | $108.5M |
| Total assets | $742.9M | $748.2M | $632.8M | $596.5M | $577.7M |
| Total liabilities | $156.6M | $161.9M | — | — | — |
| Stockholders' equity | $533.1M | $532.1M | $497.2M | $434.5M | $395.1M |
| Cash and investments | $158.4M | $181.8M | $330.4M | $288.4M | $239.8M |
| Total debt | $18.0M | $16.2M | $12.4M | $14.6M | $17.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Oct 5, 2026 | Oct 5, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jul 4, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 20, 2026 | May 20, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Apr 4, 2026 |
All 1001 Usana Health Sciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.